1. Home
  2. VYGR vs SLND Comparison

VYGR vs SLND Comparison

Compare VYGR & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • SLND
  • Stock Information
  • Founded
  • VYGR 2013
  • SLND 1900
  • Country
  • VYGR United States
  • SLND United States
  • Employees
  • VYGR N/A
  • SLND N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • SLND Military/Government/Technical
  • Sector
  • VYGR Health Care
  • SLND Industrials
  • Exchange
  • VYGR Nasdaq
  • SLND Nasdaq
  • Market Cap
  • VYGR 231.9M
  • SLND 210.6M
  • IPO Year
  • VYGR 2015
  • SLND N/A
  • Fundamental
  • Price
  • VYGR $4.21
  • SLND $4.30
  • Analyst Decision
  • VYGR Strong Buy
  • SLND Buy
  • Analyst Count
  • VYGR 8
  • SLND 2
  • Target Price
  • VYGR $16.71
  • SLND $4.50
  • AVG Volume (30 Days)
  • VYGR 635.7K
  • SLND 48.8K
  • Earning Date
  • VYGR 11-11-2025
  • SLND 11-11-2025
  • Dividend Yield
  • VYGR N/A
  • SLND N/A
  • EPS Growth
  • VYGR N/A
  • SLND N/A
  • EPS
  • VYGR N/A
  • SLND N/A
  • Revenue
  • VYGR $42,580,000.00
  • SLND $895,438,000.00
  • Revenue This Year
  • VYGR N/A
  • SLND N/A
  • Revenue Next Year
  • VYGR $107.07
  • SLND $1.10
  • P/E Ratio
  • VYGR N/A
  • SLND N/A
  • Revenue Growth
  • VYGR N/A
  • SLND N/A
  • 52 Week Low
  • VYGR $2.65
  • SLND $1.85
  • 52 Week High
  • VYGR $8.28
  • SLND $4.90
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 62.64
  • SLND 55.01
  • Support Level
  • VYGR $3.91
  • SLND $3.95
  • Resistance Level
  • VYGR $4.51
  • SLND $4.35
  • Average True Range (ATR)
  • VYGR 0.27
  • SLND 0.16
  • MACD
  • VYGR 0.05
  • SLND 0.03
  • Stochastic Oscillator
  • VYGR 74.79
  • SLND 71.43

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About SLND Southland Holdings Inc.

Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.

Share on Social Networks: